ReviewCurrent cardiology reports2025
Interleukin-6 in Cardiogenic Shock.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood Count-Based Inflammatory Indices Do Not Improve Prediction of Acute Kidney Injury in Cardiogenic Shock.Journal of clinical medicine research · 2026Review
- Extracorporeal Cytokine Adsorption in Acute Cardiovascular Care: Pathophysiological Insights and Clinical Perspectives.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewCardiogenic shock (CS) is one of the leading causes of mortality in patients with acute cardiac disease, and systemic inflammation plays a critical role in its pathophysiology. This review explores the role of interleukin-6 (IL-6) in CS, with a focus on its biological pathways, prognostic value, and potential as a therapeutic target, highlighting the importance of addressing inflammation in this context. RECENT
findingsRecent evidence highlights systemic inflammation implied in CS progression. Among the various cytokines involved, IL-6 is a major pro-inflammatory cytokine associated with organ dysfunction, and high mortality rates in acute myocardial infarction complicated by CS. Mechanistic studies exhibited an involvement of IL-6 since the first stages of CS onset, suggesting its role as both a biomarker and likely a mediator of CS. IL-6 emerges as a key inflammatory mediator in CS pathophysiology, serving as a prognostic biomarker and a potential therapeutic target. Future research should focus on further understanding the underlying mechanism linking acute inflammation and CS, patient phenotyping, and optimizing anti-inflammatory strategies investigating IL-6-targeted therapies to improve outcomes in this poor prognosis condition. Clinical trials of IL-6 blockade in cardiogenic shock are lacking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.